phrykt

Zura Bio Ltd (ZURA): who owns it and who trades it

As of Nov 16, 2026, ZURA insiders reported 1 purchase worth $12.5M in the last 12 months. The largest buyer was Access Industries Holdings LLC (10% owner), with $12.5M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Zura Bio

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ZURA

95 funds and institutions reported ZURA shares worth $430M at the end of Q2 2026, about 77% of the company. The largest holder is Montanova Capital, LLC with 10.0%.

Funds and institutions (13F) 77%Everyone else 23%

10 largest owners, by share of the company

Montanova Capital, LLC10.0%
Venrock Adviser, LLC6.8%
Mpm Bioimpact LLC4.7%
JPMorgan Chase & Co4.6%
Great Point Partners LLC4.4%
Braidwell LP4.2%
Siren, L.L.C.3.9%
BlackRock, Inc.3.8%
Commodore Capital LP3.4%
Adage Capital Partners Gp, L.l.c.2.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Montanova Capital, LLC9.44M9.95%$55.7M+4%
Venrock Adviser, LLC6.43M6.78%$38MNo change
Mpm Bioimpact LLC4.47M4.71%$26.4MNew
JPMorgan Chase & Co4.35M4.59%$24.5MNew
Great Point Partners LLC4.22M4.44%$24.9MNo change
Braidwell LP3.98M4.20%$23.5M-0%
Siren, L.L.C.3.73M3.94%$22MNo change
BlackRock, Inc.3.61M3.81%$21.3M+690%
Commodore Capital LP3.25M3.43%$19.2MNo change
Adage Capital Partners Gp, L.l.c.2.75M2.90%$16.2MNo change
Saturn V Capital Management LP2.10M2.21%$12.4M+184%
QVT Financial LP1.90M2.00%$11.2M+45%
ADAR1 Capital Management, LLC1.76M1.85%$10.4M+179%
Armistice Capital, LLC1.64M1.72%$9.7M+9%
Geode Capital Management, LLC1.58M1.67%$9.3M+200%
Affinity Asset Advisors, LLC1.46M1.54%$8.6M-43%
Stempoint Capital LP1.37M1.44%$8.1M-9%
Ikarian Capital, LLC1.22M1.28%$7.2M+2%
EcoR1 Capital, LLC1.18M1.24%$7MNo change
Vestal Point Capital, LP1.17M1.24%$6.9M+130%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ZURA insiders reported $12.5M of open-market purchases and $0 of sales.

Purchases, 12 months
$12.5M
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Feb 26, 2026
Filed Mar 2, 2026

Purchases and sales by month

$12.5M$12.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Feb 26, 2026Access Industries Holdings LLC +310% ownerPurchase2.00M$6.25$12.5MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Access Industries Holdings LLC10% owner$12.5M–Feb 26, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ZURA short interest

Moderate short interest. 8.8% of ZURA shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 36%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.47M ZURA shares were sold short, 8.8% of the shares outstanding, up 20.7% from the report before. At the average daily volume of 4.73M shares, buying them all back would take about 1.8 trading days (days to cover).

Shares short, % of all shares

8.79%May 15Oct 3012.8%

Days to cover

1.8May 15Oct 3022.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.47M8.79%+21%4.73M1.8
Oct 15, 20267.02M7.32%-25%4.78M1.5
Sep 30, 20269.37M9.77%+0%1.96M4.8
Sep 15, 20269.34M9.75%-16%1.46M6.4
Aug 31, 202611.10M11.58%-3%1.91M5.8
Aug 14, 202611.44M11.94%+9%889,78512.9
Jul 31, 202610.51M11.08%+3%536,90219.6
Jul 15, 202610.25M10.81%+11%1.08M9.5
Jun 30, 20269.24M9.74%+57%2.28M4.0
Jun 15, 20265.87M6.19%-6%1.09M5.4
May 29, 20266.22M6.56%-0%685,3619.1
May 15, 20266.24M6.58%-11%675,7299.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Zura Bio company events

Zura Bio filed 19 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026AnnouncementZura Bio Limited, a Cayman Islands exempted company, issued a press release providing a clinical update on the Company’s Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa. Filing
  2. Oct 27, 2026ResultsReleased financial results. Filing
  3. Aug 17, 2026AnnouncementShared information with investors. Filing
  4. Aug 11, 2026ResultsReleased financial results. Filing
  5. Jul 1, 2026AnnouncementShared information with investors. Filing
  6. Jun 18, 2026LeadershipZura Bio Limited held its Annual General Meeting of Shareholders, at which a quorum was present. Filing
  7. May 22, 2026LeadershipSomeit Sidhu notified Zura Bio Limited of his decision to resign from the board of directors of the Company effective as of May 21, 2026. Filing
  8. May 7, 2026ResultsReleased financial results. Filing
  9. Apr 23, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  10. Mar 19, 2026ResultsReleased financial results. Filing
  11. Mar 10, 2026AnnouncementShared information with investors. Filing
  12. Mar 5, 2026AnnouncementShared information with investors. Filing
  13. Feb 26, 2026AgreementZura Bio Limited (the “ Company ’) entered into an underwriting agreement with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters listed therein, pursuant to which the Company agreed to issue and sell 18,200,000 Class A ordinary… Filing
  14. Feb 23, 2026LeadershipNeil Graham notified Zura Bio Limited of his decision to resign from the Company’s board of directors, effective February 21, 2026. Filing
  15. Feb 11, 2026AnnouncementShared information with investors. Filing
  16. Jan 26, 2026LeadershipRobert Lisicki notified the Board of Directors of Zura Bio Limited that he was resigning as the Company’s Chief Executive Officer, principal executive officer and member of the Board, effective as of January 21, 2026. Filing
  17. Jan 12, 2026AnnouncementThe Company issued a press release announcing certain corporate and clinical trial updates and its outlook for 2026, including updates on the Company’s cash runway and expected topline data readout timelines for its two ongoing Phase 2 clinical studies of tibulizumab, the Company’s lead… Filing
  18. Jan 2, 2026AgreementZura Bio Limited and its subsidiaries, Athanor Capital, an exempted company incorporated under the laws of the Cayman Islands with limited liability, Stone Peach Properties LLC, a Georgia limited liability company and its principals, and BAFFX17, a limited company incorporated under the laws of… Filing
  19. Dec 17, 2025LeadershipArnout Ploos van Amstel notified Zura Bio Limited of his decision to resign from the Board of Directors of the Company and as a member of the Nominating and Governance Committee of the Board effective immediately. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Zura Bio financials

Famous investors that hold ZURA

3 of the 50 well-known investors we track reported holding ZURA in their latest 13F filing. The largest position is Ken Griffin's, worth $3.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026939,784$3.9M0.0%+213%
Israel Englander · Millennium ManagementQ3 2026745,761$3.1M0.0%+442%
Jim Simons · Renaissance TechnologiesQ3 202650,700$211K0.0%-84%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Zura Bio Ltd (ZURA) stock

Who owns the most ZURA stock?

The largest reported owner of Zura Bio Ltd (ZURA) is Montanova Capital, LLC, with 10.0% of the company. In total, 95 funds and institutions reported holding ZURA at the end of Q2 2026, together about 77% of the shares. See the largest owners.

Are ZURA insiders buying or selling?

In the last 12 months, ZURA insiders reported 1 open-market purchase worth $12.5M and no sales. The latest trade was on Feb 26, 2026. See every trade.

What is the short interest in ZURA?

As of Oct 30, 2026, 8.47M ZURA shares were sold short, 8.8% of the shares outstanding, up 20.7% from the report before. At the average daily volume of 4.73M shares, buying them all back would take about 1.8 trading days (days to cover). See the history.

Which famous investors hold ZURA?

3 of the 50 well-known investors we track reported ZURA in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $3.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.